# Torrent Pharmaceuticals (NSE: TORNTPHARM) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/TORNTPHARM · Pivot · prices to 22 Oct 2026

Torrent Pharmaceuticals (NSE: TORNTPHARM) closed at ₹4,604.50 on 22 Oct 2026, up 1.31% on the day. With a market capitalisation of ₹1,75,140 Cr, it ranks 52nd by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 72.1× trailing earnings, against a return on equity of 25.8% in FY26. Over the past year the share price has risen 30.9%. Its 52-week range is ₹3,532.60 (6 Nov 2025) to ₹5,250.00 (3 Aug 2026); the last close is 12.3% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹4,835 Cr (+54.6% year on year) and net profit ₹566 Cr (+3.3%), on a consolidated basis. Promoters held 60.78% of the company as of 20 Jul 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹4,604.50 |
| Market cap | ₹1,75,140 Cr |
| P/E (trailing) | 72.1 |
| ROE | 25.8% (FY26) |
| ROCE | 9.3% (FY26) |
| Debt to equity | 1.76 |
| 52-week high | ₹5,250.00 (3 Aug 2026) |
| 52-week low | ₹3,532.60 (6 Nov 2025) |
| 1-year return | +30.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹4,835 Cr | +54.6% | ₹566 Cr | +3.3% | ₹14.87 |
| Q4 FY26 | ₹4,128 Cr | +41.9% | ₹364 Cr | −26.9% | ₹11.51 |
| Q3 FY26 | ₹3,251 Cr | +15.7% | ₹635 Cr | +26.2% | ₹18.77 |
| Q2 FY26 | ₹3,246 Cr | +12.4% | ₹591 Cr | +30.5% | ₹17.45 |
| Q1 FY26 | ₹3,128 Cr | +11.1% | ₹548 Cr | +19.9% | ₹16.19 |
| Q4 FY25 | ₹2,909 Cr | +6.0% | ₹498 Cr | +10.9% | ₹14.71 |
| Q3 FY25 | ₹2,809 Cr | +2.8% | ₹503 Cr | +13.5% | ₹14.88 |
| Q2 FY25 | ₹2,889 Cr | +8.6% | ₹453 Cr | +17.4% | ₹13.37 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹13,980 Cr | ₹2,138 Cr |
| FY25 | ₹11,516 Cr | ₹1,911 Cr |
| FY24 | ₹10,728 Cr | ₹1,656 Cr |
| FY23 | ₹9,620 Cr | ₹1,245 Cr |
| FY22 | ₹8,508 Cr | ₹777 Cr |
| FY21 | ₹8,005 Cr | ₹1,252 Cr |

## Shareholding (20 Jul 2026)

- Promoters: 60.78%
- Foreign institutions: 17.97%
- Domestic institutions: 12.87%
- Non-institutions: 8.38%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sun Pharmaceutical Industries](https://app.pivotnow.in/stock/SUNPHARMA) | ₹1,744.40 | ₹4,18,540 Cr | 36.5 | — |
| [Divi's Laboratories](https://app.pivotnow.in/stock/DIVISLAB) | ₹9,141.00 | ₹2,42,665 Cr | 94.6 | — |
| [Zydus Lifesciences](https://app.pivotnow.in/stock/ZYDUSLIFE) | ₹1,123.00 | ₹1,12,020 Cr | 22.4 | — |
| [Apollo Hospitals Enterprise](https://app.pivotnow.in/stock/APOLLOHOSP) | ₹7,569.50 | ₹1,08,838 Cr | 56 | — |
| [Laurus Labs](https://app.pivotnow.in/stock/LAURUSLABS) | ₹2,010.10 | ₹1,08,596 Cr | 121.7 | — |
| [Cipla](https://app.pivotnow.in/stock/CIPLA) | ₹1,312.60 | ₹1,06,038 Cr | 27.3 | — |

## Questions and answers

### What is the share price of Torrent Pharmaceuticals today?

Torrent Pharmaceuticals (NSE: TORNTPHARM) last closed at ₹4,604.50 on 22 Oct 2026. Its 52-week high is ₹5,250.00 and its 52-week low is ₹3,532.60.

### What is the market cap of Torrent Pharmaceuticals?

Torrent Pharmaceuticals' market capitalisation is ₹1,75,140 Cr (₹1.75 lakh Cr) at the 22 Oct 2026 close, ranking 52nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Torrent Pharmaceuticals?

Torrent Pharmaceuticals trades at a trailing P/E of 72.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 56.

### What is the ROE and ROCE of Torrent Pharmaceuticals?

Return on equity was 25.8% in FY26 and return on capital employed was 9.3% in FY26 (consolidated figures).

### Is Torrent Pharmaceuticals a debt-free company?

No. Torrent Pharmaceuticals' debt-to-equity ratio was 1.76 in FY26, with total debt of ₹11,651 Cr.

### What were Torrent Pharmaceuticals' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Torrent Pharmaceuticals reported revenue of ₹4,835 Cr, +54.6% year on year, and net profit of ₹566 Cr, +3.3% year on year.

### How has Torrent Pharmaceuticals stock performed over the last year?

Torrent Pharmaceuticals' share price has risen 30.9% over the past year, −8.6% over three months and −7.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Torrent Pharmaceuticals?

As of 20 Jul 2026: promoters 60.78%, foreign institutions 17.97%, domestic institutions 12.87%, non-institutions 8.38%.

### Who are Torrent Pharmaceuticals' competitors?

The listed Pharma & Healthcare companies closest to Torrent Pharmaceuticals by market cap are Sun Pharmaceutical Industries, Divi's Laboratories, Zydus Lifesciences, Apollo Hospitals Enterprise, Laurus Labs and Cipla.

### Is Torrent Pharmaceuticals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Torrent Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TORNTPHARM against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.